Armata director granted 25,640 stock options

Armata Pharmaceuticals director Sarah J. Schlesinger reported a grant of 25,640 stock options.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Armata Pharmaceuticals director Sarah J. Schlesinger reported a grant of 25,640 stock options. These options give her the right to buy 25,640 shares of Armata common stock at an exercise price of $11.61 per share and are held as a direct derivative position.

The options were awarded on March 9, 2026 as a compensation-related grant with no cash paid by her at grant. They will vest in full on March 9, 2027, as long as she continues to serve through that date, and are scheduled to expire on March 9, 2036 if not exercised.

Insider Trade Summary

Grant/Award: 25,640 shares

Grant/Award 1 txn

Insider Schlesinger Sarah J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	25,640	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to Buy) — 25,640 contracts (Direct)

Footnotes (1)

F1. The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Armata Pharmaceuticals (ARMP) director Sarah Schlesinger report?

Sarah J. Schlesinger reported receiving 25,640 stock options as a grant. The options allow her to purchase Armata Pharmaceuticals common stock at $11.61 per share, reflecting a compensation award rather than an open-market share purchase or sale.

What are the key terms of Sarah Schlesinger’s 25,640 Armata (ARMP) stock options?

She was granted 25,640 stock options with an exercise price of $11.61 per share. The options were issued on March 9, 2026 and give her the right to buy an equal number of Armata common shares if she chooses to exercise.

When do Sarah Schlesinger’s Armata Pharmaceuticals (ARMP) stock options vest?

The 25,640 stock options will vest in full on March 9, 2027. Vesting is conditioned on her continuous service through that date, meaning she must remain in her role until then for the options to become exercisable.

When do the 25,640 Armata (ARMP) stock options granted to Sarah Schlesinger expire?

These stock options are scheduled to expire on March 9, 2036. If they are not exercised by that expiration date, the right to purchase the underlying 25,640 shares of Armata common stock at $11.61 per share will lapse.

Did Sarah Schlesinger buy or sell Armata (ARMP) shares in this Form 4 filing?

She did not buy or sell shares on the open market in this filing. Instead, she received a grant of 25,640 stock options as a compensation-related award, which may be exercised in the future under the stated terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/11/2026 - 09:14 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schlesinger Sarah J.

(Last)

(First)

(Middle)

5005 MCCONNELL AVENUE

(Street)

LOS ANGELES

90066

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Armata Pharmaceuticals, Inc. [ ARMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$11.61	03/09/2026		A		25,640		⁽¹⁾	03/09/2036	Common Stock	25,640	$0.00	25,640	D

Explanation of Responses:

1. The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.

	/s/ Sarah J. Schlesinger	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR